Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 8/20 | 0.35 |
| ▸ | HRH2 | P25021 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | PREP | P48147 | 3/20 | 0.30 |
| ▸ | CFD | P00746 | 1/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
| ▸ | FDPS | P14324 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6175339 | 0.77 | DPP4 (0.57) | DPP4OPRM1OPRD1 | |
| SCHEMBL6175345 | 0.77 | DPP4 (0.57) | DPP4OPRM1OPRD1 | |
| SCHEMBL7416194 | 0.77 | DPP4 (0.57) | DPP4OPRM1OPRD1 | |
| SCHEMBL7190126 | 0.73 | DPP4 (0.52) | DPP4OPRM1OPRD1 | |
| SCHEMBL7190130 | 0.73 | DPP4 (0.52) | DPP4OPRM1OPRD1 | |
| SCHEMBL1023051 | 0.72 | ACE (0.35) | — | |
| SCHEMBL7182927 | 0.69 | SLC6A1 (0.41) | DPP4 | |
| SCHEMBL7597019 | 0.64 | DPP4 (0.59) | DPP4 | |
| SCHEMBL13347218 | 0.64 | DPP4 (0.58) | DPP4PREP | |
| SCHEMBL13417302 | 0.64 | DPP4 (0.58) | DPP4PREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6645995-B2 | Dipeptidyl peptidase-IV (DPP-IV); treating type II diabetes in a human; amino acid amides of 2-cyanopyrrolidine | NOVO NORDISK A/S (DK) | 2003-11-11 | — | — | US | disclosed |
| US-20020103384-A1 | Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV | KANSTRUP ANDERS (DK) | 2002-08-01 | — | — | US | disclosed |
| US-6380398-B2 | COMPOUNDS SUCH AS (S,S)1-(2-AMINO-3,3-DIMETHYL-BUTYRYL)-2,5-DIHYDRO-1H-PYRROLE-2 -CARBONITRILE ADMINISTERED AS ANTIDIABETIC AGENTS; DIPEPTIDYL PEPTIDASE-IV (DPP-IV) | NOVO NORDISK A/S (DK) | 2002-04-30 | — | — | US | disclosed |
| US-20010031780-A1 | New therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV | NOVO NORDISK A/S (DK) | 2001-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031780-A1 | New therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV | DPP4, DPP7, DPP9 | DPP4 1/4885HRH2 1496/4885HRH1 1556/4885 |
| US-20020103384-A1 | Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV | DPP4, DPP7, DPP9 | DPP4 1/4885HRH2 1501/4885HRH1 1562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.